Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (467)	2/3/2009 10:25:16 PM
From: DewDiligence_on_SI	1 Recommendation Respond to of 508

But my main point was that ultimately the FDA doesn't seem to hold unsuccessful trials against you if you can come up with two successful trials. Agreed—the FDA historically has not imposed a penalty for missed trials (although perhaps they ought to figure out a way to do this objectively). Hence, I’m inclined to agree that ITMN’s chances for eventual approval are very good even if they come up short on this review cycle. As far as I know, the EMEA’s M.O. on this matter is similar to the FDA’s.